One or more of the following drugs will also be offered depending on the genetic profile of the tumour: futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib, encorafenib and binimetinib.

One or more of the following drugs will also be offered depending on the genetic profile of the tumour: futibatinib, ivosidenib, zanidatamab, trastuzumab, neratinib, encorafenib and binimetinib.

In the new study, patients diagnosed with the three main types of bile duct cancer (intrahepatic, perihilar or distal ...

The 2024 ELN risk stratification was developed with evidence from an exploratory analysis of pooled data from the phase 3 VIALE-A trial and a phase 1 b study of azacitidine plus venetoclax. The ...